Metropolis healthcare has completed the allotment of equity shares to employees under its employee stock compensation program. The Nomination and Remuneration Committee approved the allotment through a circular resolution dated January 13, 2026, demonstrating the company's commitment to employee incentivization through equity participation.

Share Allotment Details

The allotment encompasses 9,960 equity shares issued under the Metropolis Restrictive Stock Unit Plan 2020. The key parameters of this allotment are presented below:

Post-Allotment Capital Structure

Following this equity allotment, the company's capital structure has been updated accordingly. The distinctive numbers for the newly allotted shares range from 5,18,21,983 to 5,18,31,942 (both inclusive).

Lock-in Provisions and Share Rights

The allotted equity shares are subject to specific lock-in arrangements designed to ensure employee retention and alignment with company objectives. Under the terms of the MHL-RSU Plan 2020:

• 50% of the equity shares allotted to each RSU holder are subject to lock-in restrictions
• The lock-in period extends for one year from the date of allotment
• Lock-in expiry date is set for January 13, 2027
• All newly allotted shares rank pari-passu with existing equity shares in all respects

Regulatory Compliance

The allotment has been conducted in full compliance with regulatory requirements under SEBI regulations. The company obtained necessary approvals from both BSE Limited (Case No. 130335) and National Stock Exchange of India Ltd. (Application No. 27089). The original filing for the employee benefits scheme was completed on May 23, 2021, with in-principle approvals received from both exchanges in June 2021.

The shares have been issued in dematerialized form and will be available for trading subject to the applicable lock-in provisions. The company has fulfilled all disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Metropolis Healthcare has launched a Centre for Genomics to significantly expand its specialty diagnostics capabilities in India. The company plans to more than double its genomics test menu from the current 220 tests to 500 over the next two years, marking a major strategic expansion in advanced diagnostics.

Strategic Focus on Genomics Testing

Executive Chairperson Ameera Shah explained that genomics tests differ fundamentally from routine pathology tests like cholesterol or blood sugar screenings. These specialized tests target cancer, stroke, immune disorders and rare genetic conditions, where identifying underlying mutations enables doctors to select appropriate treatments more quickly and accurately.

"Genomics is not just another test," Shah emphasized. "It changes how we diagnose and predict diseases." She noted that inaccurate diagnoses often lead patients to try multiple drugs without success, while genomics allows doctors to act earlier with greater clarity.

Revenue Contribution and Growth Strategy

The company's specialty testing segment demonstrates strong performance metrics:

Shah explained that while margins in percentage terms may be lower than routine pathology tests, earnings per patient are higher because multiple tests are typically conducted from a single sample. The genomics segment is expected to support margin expansion over time by improving service quality and depth.

Comprehensive Genomics Approach

Metropolis is positioning itself uniquely in the Indian market by combining multiple elements at its new Centre for Genomics:

• Genomics testing capabilities
• Genetic counselling services
• Clinical expertise
• Bioinformatics support

Shah noted that only a small number of laboratories in India currently offer genomics testing, presenting a significant market opportunity for expansion.

Expansion and Acquisition Strategy

The company is pursuing a balanced growth approach across multiple fronts. For genomics, Metropolis plans to build capabilities internally rather than through acquisitions in this specific segment. However, the company will continue selective "bolt-on" acquisitions in other areas, similar to recent deals in Dehradun, Agra and Kolhapur to expand its network reach.

Radiology Services Development

Metropolis is also expanding its radiology offerings beyond current basic services:

This diversification strategy aims to provide comprehensive diagnostic solutions under one platform.

Market Position

Metropolis Healthcare currently maintains a market capitalization of approximately ₹9,838.00 crore. The company's shares have remained relatively stable over the past year as it focuses on building long-term capabilities in specialty diagnostics and genomics testing.